Beta
Insulin Detemir
medication Under reviewA long-acting human insulin analog used to improve glycemic control in patients with diabetes mellitus.
Research summary
Insulin detemir is a prescription medication indicated for diabetes, not a general supplement for healthy individuals. Nearly all clinical research focuses on people with type 1 or type 2 diabetes, evaluating its efficacy and safety as a basal insulin replacement. There is essentially no evidence supporting its use for performance enhancement, metabolic optimization, or other benefits in healthy, non-diabetic humans. In diabetic populations, randomized trials and observational studies show that insulin detemir offers glycemic control comparable to other basal insulins, with advantages in lower risk of nocturnal hypoglycemia, reduced glycemic variability, and less weight gain versus NPH and often versus other long-acting analogs. However, in healthy individuals, exogenous insulin use poses a clear risk of hypoglycemia without any established health benefit. For this reason, insulin detemir should be regarded strictly as a therapeutic drug for diabetes management rather than a supplement for healthy people.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Related health conditions
Research showing how this habit affects specific health conditions. Always consult healthcare professionals.
May Help With
Metabolic disorder characterized by high blood sugar and insulin resistance
Observational study of once-daily insulin detemir in people with type 2 diabetes aged 75 years and older
Lipska KJ, Bailey TS, Bekker Hansen B, Holst JJ, et al.
Effects of insulin detemir versus insulin glargine on food intake and satiety factors in type 1 diabetes
Martin K, Rincon F, et al.
Safety of insulin detemir (Levemir) in healthy volunteers: phase 1 pharmacokinetic study
Novo Nordisk A/S
Autoimmune condition where the pancreas produces little or no insulin
Observational study of once-daily insulin detemir in people with type 2 diabetes aged 75 years and older
Lipska KJ, Bailey TS, Bekker Hansen B, Holst JJ, et al.
Effects of insulin detemir versus insulin glargine on food intake and satiety factors in type 1 diabetes
Martin K, Rincon F, et al.
Research (3 studies)
Effects of insulin detemir versus insulin glargine on food intake and satiety factors in type 1 diabetes
Martin K, Rincon F, et al.
Observational study of once-daily insulin detemir in people with type 2 diabetes aged 75 years and older
Lipska KJ, Bailey TS, Bekker Hansen B, Holst JJ, et al.
Safety of insulin detemir (Levemir) in healthy volunteers: phase 1 pharmacokinetic study
Novo Nordisk A/S
Community updates
No updates yet for this supplement.
Be the first to share your experience!